Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407458 | 0.83 | CYP2C19 (0.32) | CYP2C19KDM4EALDH1A1TSHRCETP | |
| SCHEMBL14127769 | 0.82 | CETP (0.33) | CYP2C19ALDH1A1ALOX15TSHRCETP | |
| SCHEMBL18191201 | 0.80 | CYP2C19 (0.38) | CYP2C19TSHRCETP | |
| SCHEMBL1744236 | 0.79 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL857043 | 0.79 | MME (0.46) | NPSR1 | |
| SCHEMBL31034835 | 0.79 | MME (0.46) | NPSR1 | |
| SCHEMBL165219 | 0.77 | CYP2C19 (0.34) | CYP2C19 | |
| Hydrochloric Acid SCHEMBL856898 | 0.77 | MME (0.45) | NPSR1 | |
| SCHEMBL4284429 | 0.74 | LMNA (0.30) | LMNA | |
| SCHEMBL6386119 | 0.74 | FFAR3 (0.34) | CYP2C19CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118561689-A | Preparation method of 3-oxo-cyclobutanecarboxylic acid ester compound | 中节能万润股份有限公司 | 2024-08-30 | — | — | CN | claimed |
| WO-2025056065-A1 | CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE | 上海医药集团股份有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119638669-A | Chemokine receptor antagonist, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3152206-A1 | ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188051-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-6291520-B1 | INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES | PFIZER | 2001-09-18 | — | — | US | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |